JP2016510747A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510747A5
JP2016510747A5 JP2015561608A JP2015561608A JP2016510747A5 JP 2016510747 A5 JP2016510747 A5 JP 2016510747A5 JP 2015561608 A JP2015561608 A JP 2015561608A JP 2015561608 A JP2015561608 A JP 2015561608A JP 2016510747 A5 JP2016510747 A5 JP 2016510747A5
Authority
JP
Japan
Prior art keywords
solid oral
oral dosage
dosage form
mixture
citric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015561608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510747A (ja
JP6375314B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/020763 external-priority patent/WO2014138241A1/en
Publication of JP2016510747A publication Critical patent/JP2016510747A/ja
Publication of JP2016510747A5 publication Critical patent/JP2016510747A5/ja
Application granted granted Critical
Publication of JP6375314B2 publication Critical patent/JP6375314B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015561608A 2013-03-05 2014-03-05 固体経口投与剤 Expired - Fee Related JP6375314B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361772927P 2013-03-05 2013-03-05
US61/772,927 2013-03-05
US201461925443P 2014-01-09 2014-01-09
US61/925,443 2014-01-09
PCT/US2014/020763 WO2014138241A1 (en) 2013-03-05 2014-03-05 Pharmaceuticals for oral delivery

Publications (3)

Publication Number Publication Date
JP2016510747A JP2016510747A (ja) 2016-04-11
JP2016510747A5 true JP2016510747A5 (enExample) 2017-04-06
JP6375314B2 JP6375314B2 (ja) 2018-08-15

Family

ID=50391422

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015561608A Expired - Fee Related JP6375314B2 (ja) 2013-03-05 2014-03-05 固体経口投与剤

Country Status (10)

Country Link
US (4) US9457086B2 (enExample)
EP (1) EP2964193B1 (enExample)
JP (1) JP6375314B2 (enExample)
CN (1) CN105101950B (enExample)
AU (3) AU2014225822B2 (enExample)
CA (1) CA2904327C (enExample)
DK (1) DK2964193T3 (enExample)
ES (1) ES2774962T3 (enExample)
IL (1) IL240666A0 (enExample)
WO (1) WO2014138241A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US9457086B2 (en) 2013-03-05 2016-10-04 Enteris Biopharma, Inc. Pharmaceuticals for oral delivery
CA2973099C (en) 2015-01-12 2021-09-14 Enteris Biopharma, Inc. Solid oral dosage forms
AU2021213767A1 (en) 2020-01-28 2022-07-28 Genentech, Inc. IL15/IL15R alpha heterodimeric Fc-fusion proteins for the treatment of cancer
CN119630685A (zh) 2022-06-13 2025-03-14 B.A.I.实验室有限责任公司 结合白介素-13的环状寡肽及其使用方法
US12466883B1 (en) 2024-05-13 2025-11-11 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956926A (en) * 1958-09-23 1960-10-18 American Cyanamid Co Coated citric acid particles
NZ196348A (en) * 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered antibiotics
JPS57146723A (en) * 1981-03-06 1982-09-10 Toyo Jozo Co Ltd Pharmaceutical preparation having improved absorption
US4537772A (en) * 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
AU742270B2 (en) 1997-04-16 2001-12-20 Enteris Biopharma, Inc. Direct expression of peptides into culture media
EP1251867A4 (en) 2000-02-04 2004-12-08 Unigene Lab Inc NASAL CALCITON INFORMATION
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
CA2445860A1 (en) * 2001-04-30 2002-11-07 Shire Laboratories Inc. Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
WO2005072277A2 (en) * 2004-01-21 2005-08-11 Unigene Laboratories Inc. Amidated parathyroid hormone fragments and uses thereof
US8227241B2 (en) 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
WO2006026592A2 (en) 2004-08-27 2006-03-09 Spherics, Inc. Oral administration of poorly absorbed drugs, methods and compositions related thereto
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
EP1907561B1 (en) 2005-06-24 2013-08-28 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
US7449896B2 (en) * 2005-07-29 2008-11-11 Ixys Corporation Current sensor using level shift circuit
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
WO2007072911A1 (ja) * 2005-12-22 2007-06-28 Asubio Pharma Co., Ltd. 塩酸サプロプテリンの生体内吸収性を向上させた製剤
WO2007075792A1 (en) * 2005-12-22 2007-07-05 Wyeth Methods of treating gastrointestinal tract infections with tigecycline
AR060355A1 (es) * 2007-04-04 2008-06-11 Kelly Jose Luis Aparato para disipar el agua producida por equipos de climatizacion
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
TWI448301B (zh) * 2007-11-05 2014-08-11 Ala Wai Pharma Inc 用於增強經口投與之極性劑的生物可用性之調配物
US20100256060A1 (en) * 2009-04-02 2010-10-07 Unigene Laboratories Inc. Peptide pharmaceuticals for nasal delivery
WO2012040364A1 (en) 2010-09-21 2012-03-29 Unigene Laboratories Inc. Calcitonin products and therapies for treating inflammatory or degenerative diseases
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
CA2839408A1 (en) * 2011-06-14 2012-12-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
BR112013032088B1 (pt) 2011-06-15 2020-11-24 Resother Pharma Aps produtos farmacêuticos anti-inflamatórios
US9457086B2 (en) 2013-03-05 2016-10-04 Enteris Biopharma, Inc. Pharmaceuticals for oral delivery
CA2973099C (en) 2015-01-12 2021-09-14 Enteris Biopharma, Inc. Solid oral dosage forms

Similar Documents

Publication Publication Date Title
JP2015527402A5 (enExample)
JP2015078230A5 (enExample)
JP2017537066A5 (enExample)
JP2018506575A5 (enExample)
JP2012255026A5 (enExample)
JP2017105763A5 (enExample)
JP2016534153A5 (enExample)
JP2014139229A5 (enExample)
JP2010529999A5 (enExample)
JP2015509788A5 (enExample)
JP2014129360A5 (enExample)
JP2018507914A5 (enExample)
JP2018529656A5 (enExample)
JP2015057436A5 (enExample)
JP2015525763A5 (enExample)
JP2016503030A5 (enExample)
JP2013524782A5 (enExample)
JP2016534142A5 (enExample)
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
JP2013542945A5 (enExample)
JP2014511393A5 (enExample)
CL2014002896A1 (es) Una formulacion farmaceutica en la forma de una tableta recubierta que consiste de a) un nucleo obtenido a partir de una co-mezcla de manitol, croscarmelosa de sodio y al menos un compuestos activo, y b) un recubrimiento el cual se aplica en la forma de una solucion acuosa o que contiene agua y alcohol, y donde la tableta se desintegra rapidamente en presencia de humedad; y su proceso de preparacion.
JP2017518982A5 (enExample)
JP2017532316A5 (enExample)
JP2014521641A5 (enExample)